What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · AMGN, LLY, NVO

Eli Lilly's next-gen weight-loss drug crushes it in trials — load up on obesity drug stocks

Eli Lilly just released highly anticipated results for its next-gen weight-loss drug, and the data looks incredibly promising. Analysts are cheering, saying the company's lineup is strong enough to dominate the multi-billion dollar obesity market for years.

Idea

The weight-loss drug market is turning into a gold rush, and Eli Lilly just proved it has the scientific firepower to stay at the very top of the industry. This successful trial clears a massive hurdle, practically guaranteeing a new blockbuster product that will generate billions in revenue. As the positive news lifts the entire sector, buying Lilly and its closest competitors offers a way to profit from a massive, long-term shift in global healthcare demand.

Key details

AMGN LLY NVOD#pharma#obesity#momentum#biotech

Community

Upvotes

Views

Copies

Cosigns

News sources

Campbell's Earnings Beat; Eli Lilly Obesity Drug Results | Stock Movers — Bloomberg
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug — MarketWatch

Eli Lilly's next-gen weight-loss drug crushes it in trials — load up on obesity drug stocks

Idea

Key details

Community

News sources

Related ideas

Related